Tagitanlimab
Product Specifications
UNSPSC Description
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC)[1][2].
Target Antigen
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tagitanlimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Tagitanlimab]
References & Citations
[1]Lu S, et al. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist. 2019 Feb;24(Suppl 1):S21-S30. |[2]Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15(1):2153410.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99544/Tagitanlimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99544/Tagitanlimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2417649-97-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
